Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of diabetes control on ranibizumab treatment for diabetic macular edema
2012-003943-32Phase 4Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Change in best corrected visual acuity at 12 months. Started Mar 2015; status: terminated.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2012-003943-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003943-32.